Systemic 1-methyl,4-phenyl,1-2-3-6-tetrahydropyridine (MPTP) administration decreases retinal dopamine content in primates.
Following MPTP administration, 4 Cynomolgus monkeys developed a parkinsonian syndrome, accompanied by specific changes of both pattern visual evoked potential and electroretinogram. Retinal dopamine and dihydroxyphenylacetic acid contents were measured in the 4 MPTP-treated monkeys and in 3 normal monkeys. Dopamine and dihydroxyphenylacetic acid levels were significantly lower in the retinas of the MPTP-treated animals (p less than 0.001), suggesting that dopamine has a specific function in the visual system of primates.
Ghilardi
M F
MF
Dept. of Neurology, Mount Sinai School of Medicine, New York, N.Y. 10029.
Chung
E
E
Bodis-Wollner
I
I
Dvorzniak
M
M
Glover
A
A
Onofrj
M
M
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000818:Animals; D002853:Chromatography, Liquid; D004298:Dopamine / Q000378:metabolism*; D004596:Electroretinography; D005074:Evoked Potentials, Visual / Q000187:drug effects; D005260:Female; D008252:Macaca fascicularis; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000378:metabolism* / Q000503:physiopathology; D010364:Pattern Recognition, Visual / Q000187:drug effects / Q000502:physiology; D011725:Pyridines / Q000494:pharmacology*; D012160:Retina / Q000187:drug effects / Q000378:metabolism*
D011725:Pyridines; D015102:3,4-Dihydroxyphenylacetic Acid; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D004298:Dopamine